HealingPreclinicalAnimal Studies

TB-500

Also known as Thymosin Beta-4 fragment

A synthetic 17-amino acid fragment of Thymosin Beta-4 with a longer half-life (~2-4 days) compared to the full protein (~2 hours).

Preclinical - No human clinical trials, FDA Category 2 (restricted from compounding)

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

2-2.5 mg twice weekly (loading), 2.5 mg once weekly (maintenance)

Frequency

2x weekly for 4-6 weeks, then 1x weekly

Duration

4-6 weeks loading, then maintenance

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 2-2.5 mg twice weekly (loading), 2.5 mg once weekly (maintenance) via Subcutaneous or intramuscular injection, 2x weekly for 4-6 weeks, then 1x weekly. Dose range: 2-10 mg per week during loading phase. Duration: 4-6 weeks loading, then maintenance.

Timing & Administration

Administer via Subcutaneous or intramuscular injection. Frequency: 2x weekly for 4-6 weeks, then 1x weekly.

Mechanism of Action

Promotes cell migration by binding to and sequestering actin. Upregulates actin expression, promotes angiogenesis, reduces inflammation, and facilitates hair follicle stem cell migration for wound healing.

Research Summary

Evidence level: animal studies. Clinical status: Preclinical - No human clinical trials, FDA Category 2 (restricted from compounding).

Side Effects & Safety

Important Warnings

  • Contraindicated with active cancer or cancer history
  • WADA prohibited
  • May trigger histamine release.
Injection site reactions
headache
fatigue
nausea
potential histamine release
theoretical cancer migration risk

References

No references available.